Proteo Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed

IRVINE, Calif. & KIEL, Germany--(BUSINESS WIRE)--Proteo, Inc. (OTCQB:PTEO) and its wholly-owned subsidiary Proteo Biotech AG today announced that the NHS Lothian’s Edinburgh Heart Centre has successfully completed patient recruitment and treatment for the Phase II clinical trial (EMPIRE study) with Proteo’s drug candidate Elafin for prevention of myocardial injury after coronary artery bypass surgery (CABG). According to plan top-line results from this trial are expected to be announced in the first quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.